Now we are not just an IP company. We have substantial R&D facilities and capabilities. We got about a 24,000 square foot facility in Madison, Wisconsin where our R&D happens. This can also came into the Roche acquisition and what we have there is infrastructure of it that was build by big pharma and that the small biotech would have a very difficult time replicating. And so we have substantial capabilities there.
All right, so why should you care about this well. We are responding to four market opportunities. First, pharma launch to make their APIs better. We have over 42,000 targeting sequences that we can use to target. We think virtually any type of drug to make APIs better. We think we can shift the safety profile of the drug, as well as the efficacy profile of the drug by targeting with these peptides. Second, pharma launch in Richmond strategy what we mean by that is for example if the cancer drug has increased survival by two months, but that really means is that some patients will survive two years longer and some patients will survive two weeks longer. Of course, our goal is to drive the patients that will respond to the therapy into the therapy. We have the capabilities to do that by making companion diagnostics on the back of our targeting library as well.
Next, we want to make generics better. We really like the idea of the business of taking the generic with multiple years of clinical end markets history and targeting that generic to make it either safer end or more effective being as a good business and its really straightforward business.And then finally of course Parma still needs a way to deliver siRNA, consistently and outside deliver and we have capabilities there as well. So we got multiple value creation points among these four areas and including developing drugs it will be partnered or licensed two foreseeable companies including allowing a foreseeable companies to build our platforms, yes.